Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Semax

Semax is described as a synthetic ACTH-fragment-derived heptapeptide; exact formulation and jurisdiction are essential to interpreting regional reports. Older Russian-language controlled reports describe stroke populations, but accessible methods, blinding, formulations, and independent replication are limited.

Aliases reviewed
ACTH(4-7)-Pro-Gly-Pro, Semax heptapeptide
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedOlder controlled reports in stroke patients, with limited accessible methods.
Animal/cell
Not rated
Approved medicine
Not rated

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. Research explores neurotrophic signaling, ischemia models, and neurological recovery markers.

Identity

Semax is described as a synthetic ACTH-fragment-derived heptapeptide; exact formulation and jurisdiction are essential to interpreting regional reports.

Biological mechanism or research interest

Research explores neurotrophic signaling, ischemia models, and neurological recovery markers.

Verified approved human uses

No Canadian or U.S. approved use was verified in the reviewed sources. Regional use reports are not treated as worldwide approval.

Investigational human evidence

Older Russian-language controlled reports describe stroke populations, but accessible methods, blinding, formulations, and independent replication are limited.

Cognition, focus, neuroprotection, and stroke-recovery claims are not established for an unspecified catalogue material.

Human versus animal or cell evidence

Much mechanistic literature is animal or cellular and cannot establish human clinical outcomes.

Limitations and known risks

FDA notes limited route-specific safety information and peptide impurity or immunogenicity concerns; long-term human safety is unclear.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.